• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy

tetano

Editor, Senior Moderator
PLoS One


. 2026 Mar 25;21(3):e0345639.
doi: 10.1371/journal.pone.0345639. eCollection 2026.
Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy

Xiaowu Sun[SUP] 1 [/SUP], Joseph C Cappelleri[SUP] 2 [/SUP], Laura L Lupton[SUP] 1 [/SUP], Mary M Moran[SUP] 3 [/SUP], Santiago M C Lopez[SUP] 3 [/SUP], Laura Puzniak[SUP] 3 [/SUP], Alon Yehoshua[SUP] 4 [/SUP], Manuela Di Fusco[SUP] 4 [/SUP]


Affiliations
Abstract

Background: Numerous grouping and scoring methodologies have been proposed to assess long COVID symptomatology. One approach is to use symptom count as a simple, quantifiable measure of long COVID symptom burden.
Methods: This was a secondary analysis of a nationwide patient-reported outcomes (PRO) study that recruited symptomatic adults testing positive for SARS-CoV-2 at a Retail Pharmacy in the spring of 2023. EQ-5D-5LTM, work productivity and impairment (WPAI), the Patient-Reported Outcomes Measurement Information System (PROMIS®) fatigue, and a long COVID symptom questionnaire were administered at Week 4, Month 3, and Month 6 after testing. Pre-infection EQ-5D-5L, WPAI, PROMIS fatigue were collected via recall. Cronbach's α assessed internal consistency of symptoms. Scree plots determined number of significant factors (symptoms) to retain for analysis. Spearman correlation coefficients were calculated between number of symptoms and EQ-5D-5L, WPAI, PROMIS fatigue scores and their changes from pre-COVID baseline. Categorization of long COVID burden using number of symptoms was proposed based on scores via equipercentile linking.
Results: Of 505 patients, mean age was 46.3 years, 70.7% were female. Cronbach's α was 0.865, denoting good internal consistency of the symptom survey instrument. The scree plot supported use of one factor for the composite 30-symptom list. Number of symptoms correlated strongly with EuroQol Utility Index (r = -0.53), presenteeism (r = 0.51), activity impairment (r = 0.51) and fatigue (r = 0.56). Statistically significant differences in mean number of symptoms were found between patients with versus those without problems in any of the 5 domains of the EQ-5-dimensional descriptive system. Based on linked PRO scores, subjects could be classified into low (≤2), medium (3-9), and high (≥10) symptom burden.
Conclusions: Number of long COVID symptoms correlated with validated PRO measures and identified three symptom-based categories of long COVID burden. Number of symptoms is a valid and internally consistent measure to assess long COVID burden in outpatient settings.


 
Back
Top Bottom